Medpage Today on MSN5d
Primary Biliary Cholangitis Incidence and Prevalence Growing
Primary biliary cholangitis (PBC) has typically been considered a rare condition, with a pooled global estimated incidence of ...
Medpage Today on MSN5d
Managing Primary Biliary Cholangitis Progression and Symptoms
Once clinical suspicion has been established for primary biliary cholangitis (PBC), the "serologic hallmark" of the ...
GSK's linerixibat meets primary endpoint
Drugmaker GSK said on Tuesday that its linerixibat candidate had shown "positive" Phase III results in cholestatic pruritus ...
GSK's Investigational Liver Disease Candidate Hits Primary Goal In Late-Stage Study To Treat Relentless Itch In Some Patients
On Tuesday, GSK plc (NYSE:GSK) released the headline results of the GLISTEN global phase 3 trial evaluating linerixibat in ...
pharmaphorum1d
GSK drug raises hopes for patients with PBC itch
Interim results from the ongoing GLISTEN trial of linerixibat, GSK's targeted inhibitor of the ileal bile acid transporter ...
Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from a two-and-a-half-year interim analysis from the ongoing Phase ...
Pharmabiz11h
GSK announces positive results from GLISTEN phase III trial of linerixibat in adults with cholestatic pruritus (relentless itch) associated with PBC
GSK announces positive results from GLISTEN phase III trial of linerixibat in adults with cholestatic pruritus (relentless itch) associated with PBC: London, UK Wednesday, Novembe ...
PharmiWeb2d
Iqirvo® (elafibranor) data show efficacy and tolerability for up to 3 years in patients with PBC with improvements in fatigue and pruritus
Ipsen presents three late-breaking presentations and eight abstracts across rare cholestatic liver disease portfolio at AASLD 2024Elafibranor was granted marketing authorisation for the treatment of ...
Monthly Prescribing Reference6d
FDA Denies Full Approval of Obeticholic Acid for Primary Biliary Cholangitis
The sNDA was submitted to support full approval of OCA for this indication based on data from the COBALT trial, as well as real-world evidence.
Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease
On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) revealed data from a two-and-a-half-year interim analysis from the ongoing ...